Global In Vitro Diagnostics for Cardiology and Neurology Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• March 2023, Fujirebio announced the expansion of its assay product portfolio in the field of neurodegenerative disorders with the launch of fully automated Lumipulse G NfL Blood and Lumipulse G NfL CSF tests.
• July 2023, Beckman Coulter, Inc. entered into a partnership with Fujirebio to enhance patients' access to blood-based Alzheimer’s disease tests. The partnership aims to combine the companies' immunoassay strengths to support this effort.
• March 2022, Siemens Healthineers AG received breakthrough device designation from the FDA for the sNfL test used for diagnosing multiple sclerosis. The test measures NfL in human plasma and serum, serving as a biomarker for nerve cell injuries detected in blood and cerebral spinal fluid.

In this report, the In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Technology, Product, Application, End Users and Geography.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Technology

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Technology into Clinical Chemistry, Immunoassay, Microbiology, Hematology, Molecular Diagnostics, Coagulation and Others.

Clinical Chemistry

Clinical chemistry holds a significant position in the IVD market, accounting for approximately 17% of the global share in 2024. This segment focuses on the analysis of biochemical components in bodily fluids, such as blood and urine, to diagnose and monitor various diseases. Advancements in automation and the development of point-of-care testing solutions have enhanced the efficiency and accuracy of clinical chemistry tests. The growing demand for real-time diagnostics in critical care settings and the expansion of personalized medicine are key drivers of this segment's growth.

Immunoassay

Immunoassays dominate the IVD market, capturing the largest share at approximately 26% in 2024. These assays are essential for detecting specific proteins, hormones, and antibodies, playing a crucial role in diagnosing infections, cancers, and chronic conditions. The segment's growth is propelled by the increasing prevalence of chronic and infectious diseases, along with the rising demand for early and accurate diagnosis. Innovations in immunoassay technologies, such as chemiluminescence immunoassays (CLIAs), have further enhanced their sensitivity and specificity.

Microbiology

The microbiology segment accounts for approximately 9% of the IVD market in 2024. It focuses on identifying pathogens responsible for infectious diseases through culture-based or molecular methods. The segment's growth is driven by the increasing incidence of infectious diseases, antibiotic resistance, and the need for rapid pathogen identification. Advancements in automation and the development of rapid diagnostic tests have significantly improved the efficiency and accuracy of microbiological analyses.

Hematology

Hematology represents about 5% of the IVD market in 2024, concentrating on the analysis of blood samples to diagnose conditions like anemia, infections, and blood cancers. The segment benefits from technological advancements in hematology analyzers, enabling high-throughput testing and enhanced cell counting accuracy. The integration of digital solutions for remote monitoring and the rising incidence of blood disorders contribute to the segment's growth.

Molecular Diagnostics

Molecular diagnostics hold a substantial share of the IVD market, accounting for approximately 21% in 2024. This segment utilizes nucleic acid testing to detect genetic variations and infectious agents, playing a pivotal role in personalized medicine and targeted therapies. The adoption of next-generation sequencing (NGS) and the development of rapid PCR-based tests have revolutionized disease detection and monitoring. The increasing prevalence of genetic disorders and the demand for precise diagnostic tools are key drivers of this segment.

Coagulation

Coagulation testing comprises over 8% of the IVD market in 2024, focusing on analyzing blood clotting mechanisms to diagnose bleeding disorders and monitor anticoagulant therapies. The segment's growth is fueled by the aging population, rising incidence of cardiovascular diseases, and the need for accurate monitoring of coagulation disorders. Advancements in automation and the development of point-of-care devices have enhanced the accessibility and efficiency of coagulation testing.

Others

The 'Others' category encompasses emerging technologies like flow cytometry, cytogenetics, and mass spectrometry, representing approximately 14% of the IVD market in 2024. These technologies offer advanced analytical capabilities for specialized diagnostic applications, including allergy testing, reproductive health, and neurology. The segment's growth is driven by increasing awareness and diagnosis rates, advancements in analytical techniques, and the demand for specialized diagnostic solutions in niche medical fields.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Product

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Product into Instruments and Consumables/Reagents.

Instruments

The instruments segment plays a pivotal role in the IVD market for cardiology and neurology, encompassing devices such as analyzers, imaging systems, and automated platforms that facilitate diagnostic procedures. In 2023, this segment contributed approximately 34.12% to the global market revenue. The demand for advanced diagnostic equipment is driven by the need for accurate and efficient testing methodologies, especially in clinical laboratories and hospital settings. Technological advancements and the integration of automation are further propelling the growth of this segment.

Reagents & Consumables

Accounting for a substantial 65.88% of the global market revenue in 2023, the reagents and consumables segment dominates the IVD landscape in cardiology and neurology. This category includes essential components like fluorescent tags, antibodies, protein biomarkers, and PCR reagents that are integral to various diagnostic assays. The high consumption rate of these products, coupled with ongoing research and development efforts to introduce novel biomarker kits, underscores their critical role in facilitating accurate and timely diagnoses. The segment's growth is further bolstered by the increasing prevalence of cardiovascular and neurological disorders, necessitating frequent and reliable testing solutions.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Application

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Application into Cardiology and Neurology.

Cardiology

The cardiology segment commands a substantial share of the IVD market for cardiology and neurology, accounting for about 58% of the global revenue in 2023. This growth is fueled by the rising incidence of cardiovascular diseases (CVDs), such as coronary artery disease, arrhythmias, and heart failure. The growing focus on early detection and accurate monitoring has increased the demand for advanced diagnostic tools, including biomarkers and imaging techniques. Continuous advancements in diagnostic technologies and the integration of AI-driven solutions are poised to further expand this segment.

Neurology

The neurology segment has gained traction in the IVD market, representing approximately 42% of the global share in 2023. This segment’s growth is propelled by the rising prevalence of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy. The increasing need for precise and early diagnosis has spurred innovations in molecular diagnostics and the development of novel assays. Progress in genomics and proteomics is enhancing diagnostic accuracy, while investments in research and development are driving sustained growth.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by End Users

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by End Users into Academics, Hospitals & Laboratories, Pharmaceutical & Biotechnology and Others.

Academics

Academic institutions are instrumental in propelling the IVD landscape forward, particularly in cardiology and neurology. Their research initiatives lead to groundbreaking diagnostic innovations, enhancing early detection and treatment strategies. Collaborations between academia and industry stakeholders further accelerate the translation of research findings into practical diagnostic applications.

Hospitals & Laboratories

Dominating the IVD market, hospitals and laboratories are central to the deployment of diagnostic technologies. With a commanding share of approximately 60% in 2023, these facilities prioritize the integration of cutting-edge diagnostic tools to improve patient outcomes. The emphasis on precision medicine and the management of complex cardiovascular and neurological disorders underscores the critical role of this segment.

Pharmaceutical & Biotechnology

The pharmaceutical and biotechnology sector is a significant contributor to the IVD market, leveraging diagnostic tools for drug discovery and development. Holding an estimated 25% market share in 2023, this segment's growth is fueled by the surge in personalized medicine and the necessity for companion diagnostics. The continuous pursuit of targeted therapies amplifies the demand for specialized diagnostic solutions.

Others

Encompassing diagnostic clinics, point-of-care centers, and home healthcare services, the 'Others' segment plays a pivotal role in expanding the reach of IVD technologies. Accounting for about 15% of the market in 2023, this segment's growth is driven by the increasing need for accessible and rapid diagnostic solutions, especially in remote and resource-limited settings.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Geography

In this report, the In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

In Vitro Diagnostics for Cardiology and Neurology Market Share (%), by Geographical Region

North America

North America dominates the global IVD market for cardiology and neurology, holding approximately 42.28% of the market share in 2023. This leadership is driven by a high prevalence of cardiovascular and neurological disorders, robust healthcare infrastructure, and significant investments in research and development. The region's focus on early diagnosis and personalized treatment approaches further accelerates market growth.

Europe

Europe maintains a strong presence in the IVD market, with a notable share of 28.81% in 2022. The market benefits from increased research funding, a high burden of cardiovascular diseases, and the presence of leading diagnostic companies. Countries such as the UK, France, and Germany are at the forefront, owing to their advanced healthcare systems and emphasis on early disease detection.

Asia Pacific

Asia Pacific is poised for significant growth in the IVD sector, expected to dominate the majority revenue share by 2037. Factors contributing to this surge include escalating healthcare investments, rising awareness about early diagnosis, and a growing patient population. The region's commitment to enhancing diagnostic capabilities positions it as a key player in the global market.

Middle East and Africa

The MEA region accounted for 3.6% of the global IVD market in 2022, with projections indicating a CAGR of 8.8% from 2023 to 2030. This growth is propelled by an increasing incidence of cardiovascular and neurological diseases and ongoing improvements in healthcare infrastructure. The UAE is anticipated to experience the highest growth rate within the region.

Latin America

Latin America emerges as the fastest-growing region in the IVD market, with expectations to reach USD 1,508.3 million by 2030. The region's growth is driven by technological advancements, heightened awareness of diagnostic tools, and a rising prevalence of target diseases. Brazil, in particular, is projected to play a significant role in this expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Global In Vitro Diagnostics for Cardiology and Neurology Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Aging population demand
• Technological advancements boost
• Increasing chronic diseases prevalence
• Rising healthcare expenditure

• Growing awareness campaigns: Growing awareness campaigns have been pivotal in propelling the Global In Vitro Diagnostics (IVD) market for cardiology and neurology forward. With increased focus on preventive healthcare and early detection, the demand for advanced diagnostic tools has surged. Cardiology and neurology, being critical areas of healthcare, have witnessed substantial investments in research and development, resulting in innovative diagnostic solutions. The global IVD market for cardiology and neurology is witnessing significant expansion due to rising incidences of cardiovascular diseases and neurological disorders globally. Moreover, technological advancements such as point-of-care testing and molecular diagnostics have further fueled market growth, enabling rapid and accurate diagnosis, thus improving patient outcomes.

  As awareness about the importance of early diagnosis and treatment continues to spread, the demand for IVD products in cardiology and neurology is expected to soar. Governments and healthcare organizations are increasingly emphasizing the need for screening programs and awareness campaigns to educate people about the risks associated with cardiovascular diseases and neurological disorders. Furthermore, the integration of artificial intelligence and machine learning algorithms into diagnostic systems is revolutionizing the landscape by enhancing the accuracy and efficiency of diagnostics. These trends indicate a promising future for the global IVD market for cardiology and neurology, with continuous innovations and awareness initiatives driving growth and improving patient care worldwide.

Restraints

• Stringent regulatory requirements
• High equipment costs
• Limited reimbursement policies
• Lack of skilled professionals

• Data privacy concerns: Data privacy concerns have become paramount in the era of digitalization, especially in the healthcare sector where vast amounts of sensitive patient data are generated and stored. In the context of global in vitro diagnostics for cardiology and neurology, data privacy is a critical issue due to the highly personal nature of the information involved. Patients undergoing diagnostics for cardiac and neurological conditions often share intimate details about their health, making it imperative for healthcare providers and diagnostic companies to implement robust data protection measures. From the collection of patient samples to the analysis of test results, every step of the diagnostic process must adhere to stringent privacy protocols to safeguard patient confidentiality and prevent unauthorized access or misuse of sensitive medical information.

  The global market for in vitro diagnostics in cardiology and neurology continues to expand, fueled by technological advancements and increasing demand for accurate and timely diagnostics, the need for comprehensive data privacy regulations becomes even more pressing. Regulatory bodies worldwide are enacting laws and guidelines to address data privacy concerns in healthcare, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States. Compliance with these regulations not only helps to protect patient privacy but also fosters trust between healthcare providers, diagnostic companies, and patients, ultimately supporting the continued growth and advancement of in vitro diagnostics in cardiology and neurology on a global scale.

Opportunities

• Emerging markets expansion
• Personalized medicine adoption
• Telemedicine integration
• Point-of-care testing demand

• AI and machine learning utilization: AI and machine learning have become indispensable tools in the field of in vitro diagnostics for cardiology and neurology. These advanced technologies are revolutionizing the way medical data is analyzed, enabling more accurate and efficient diagnosis and treatment planning. In cardiology, AI algorithms can analyze complex data from electrocardiograms (ECGs), echocardiograms, and other diagnostic tests to detect subtle patterns and markers of cardiovascular diseases such as arrhythmias, coronary artery disease, and heart failure. By quickly identifying abnormalities and predicting potential risks, AI-powered diagnostic tools help physicians make timely interventions and improve patient outcomes.

  Neurology, AI and machine learning play a crucial role in the interpretation of brain imaging studies like magnetic resonance imaging (MRI) and computed tomography (CT) scans. These technologies assist in the early detection and characterization of neurological conditions such as stroke, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. By analyzing large datasets and learning from patterns in medical images, AI algorithms can provide valuable insights into disease progression, guide treatment decisions, and even predict patient outcomes. The integration of AI and machine learning into in vitro diagnostics for cardiology and neurology holds great promise for enhancing diagnostic accuracy, personalized medicine, and overall healthcare efficiency.

Key players in Global In Vitro Diagnostics for Cardiology and Neurology Market include:

• Quest Diagnostics
• Alere Inc
• GE Healthcare
• Thermo Fisher Scientific
• Agilent Technologies
• Bio-Rad Laboratories
• Eurofins Scientific
• Covance
• Promega Corporation
• Merck KGaA

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis